Not Found

Find information on medical topics, symptoms, drugs, procedures, news and more, written for the health care professional.

* This is the Professional Version. *

Metachromatic Leukodystrophy

(Sulfatide Lipidosis)

By Lee M. Sanders, MD, MPH, Associate Professor of Pediatrics, Stanford University

Click here for
Patient Education

Metachromatic leukodystrophy is a sphingolipidosis, an inherited disorder of metabolism, caused by arylsulfatase A deficiency, which causes progressive paralysis and dementia resulting in death by age 10 yr.

For more information, see Table Sphingolipidosis.

In metachromatic leukodystrophy, arylsulfatase A deficiency causes metachromatic lipids to accumulate in the white matter of the CNS, peripheral nerves, kidney, spleen, and other visceral organs; accumulation in the nervous system causes central and peripheral demyelination. Numerous mutations exist; patients vary in age at onset and speed of progression.

The infantile form is characterized by progressive paralysis and dementia usually beginning before age 4 yr and resulting in death about 5 yr after onset of symptoms.

The juvenile form manifests between 4 yr and 16 yr of age with gait disturbance, intellectual impairment, and findings of peripheral neuropathy. Contrary to the infantile form, deep tendon reflexes are usually brisk. There is also a milder adult form.

Diagnosis of metachromatic leukodystrophy is suggested clinically and by findings of decreased nerve conduction velocity; it is confirmed by detecting enzyme deficiency in WBCs or cultured skin fibroblasts. (Also see testing for suspected inherited disorders of metabolism.)

There is no effective treatment for metachromatic leukodystrophy.

* This is the Professional Version. *